Table 1.
Clinicopathological characteristics.
| Variable | n | % |
|---|---|---|
| Age (years) | Median 73 (range 23–98) | |
| Tumour size (mm) | Median 20 (range 4–100) | |
| Tumour histology | ||
| Ductal | 170 | 86.3 |
| Lobular | 6 | 3.0 |
| Other | 7 | 3.6 |
| NA | 14 | 7.1 |
| Histologic grade | ||
| I | 15 | 7.6 |
| II | 96 | 48.7 |
| III | 81 | 41.1 |
| NA | 5 | 2.5 |
| ER | ||
| Positive | 183 | 92.9 |
| Negative | 9 | 4.6 |
| NA | 5 | 2.5 |
| PgR | ||
| Positive | 152 | 77.2 |
| Negative | 38 | 19.3 |
| NA | 7 | 3.6 |
| HER2 (IHC) | ||
| 0 | 122 | 61.9 |
| 1 | 41 | 20.8 |
| 2 | 19 | 9.6 |
| 3 | 3 | 1.5 |
| NA | 12 | 6.1 |
| Nodal status | ||
| Positive | 77 | 39.1 |
| Negative | 88 | 44.7 |
| NA | 32 | 16.2 |
| Vital status | ||
| Alive | 73 | 37.1 |
| Dead | 124 | 62.9 |
| Dead from breast cancer | 41 | 33.1 |
| Chemotherapy | ||
| Yes | 21 | 10.7 |
| No | 158 | 80.2 |
| NA | 18 | 9.1 |
| Endocrine therapy | ||
| Yes | 119 | 60.4 |
| No | 64 | 32.5 |
| NA | 14 | 7.1 |
| Radiotherapy | ||
| Yes | 81 | 41.1 |
| No | 98 | 49.7 |
| NA | 18 | 9.1 |
ER, estrogen receptor; HER2, human epidermal growth factor receptor 2; NA, not available; PgR, progesterone receptor.